Hims & Hers Health (NYSE:HIMS) COO Sells $398,226.53 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Michael Chi sold 14,027 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the sale, the chief operating officer directly owned 456,660 shares of the company’s stock, valued at approximately $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Down 0.3%

Shares of NYSE:HIMS traded down $0.08 during mid-day trading on Thursday, hitting $27.92. 8,214,836 shares of the company traded hands, compared to its average volume of 24,477,230. The stock has a 50-day moving average price of $30.34 and a two-hundred day moving average price of $27.51. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $65.30. The stock has a market cap of $6.51 billion, a P/E ratio of -44.32 and a beta of 2.42. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.17 earnings per share. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Hims & Hers and certain executives. The proposed class covers investors who purchased shares between August 4, 2025, and July 29, 2026, with November 2, 2026, set as the lead-plaintiff deadline. ClaimsFiler shareholder alert
• Negative Sentiment: The allegations center on potentially deceptive or unlawful privacy and billing practices, including issues connected with data sharing. These claims remain allegations, but could create legal liabilities and distract management. Hagens Berman class-action announcement
• Negative Sentiment: The legal-news flow reinforces concerns already reflected in recent selling pressure, while Hims & Hers continues to report losses and has substantial balance-sheet leverage. The stock has therefore remained volatile and below its recent 50-day average.
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, offering no new bullish catalyst or meaningful change to the current analyst view. Bank of America Hold rating

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HIMS. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft increased their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. TD Cowen boosted their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Truist Financial upped their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research note on Monday, August 24th. Finally, Barclays cut their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $32.43.

Institutional Trading of Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the stock. Bienville Capital Management LLC bought a new stake in shares of Hims & Hers Health during the second quarter valued at about $27,242,000. Engineers Gate Manager LP purchased a new stake in shares of Hims & Hers Health in the second quarter worth about $232,000. Integrated Wealth Concepts LLC bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $147,000. Baird Financial Group Inc. boosted its position in shares of Hims & Hers Health by 384.6% in the second quarter. Baird Financial Group Inc. now owns 65,575 shares of the company’s stock valued at $2,273,000 after acquiring an additional 52,043 shares during the period. Finally, Nykredit A S purchased a new position in Hims & Hers Health during the second quarter valued at approximately $222,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.